J&J beats back Viatris' generic challenge to schizophrenia med Invega Trinza

Amid a wave of patent litigation over Johnson & Johnson's portfolio of schizophrenia treatments, the company has successfully batted away a copycat challenge from Viatris.

Viatris’ proposed generics of J&J’s long-lasting Invega Trinza would "induce infringement" of the so-called '693 patent, New Jersey District Judge Evelyn Padin wrote in court documents filed this week. Viatris’ attempts to show the patent is invalid have fallen flat, Padin continued.